These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24930219)

  • 21. The role of intestinal microbiota in the pathogenesis of metabolic diseases.
    Węgielska I; Suliburska J
    Acta Sci Pol Technol Aliment; 2016; 15(2):201-211. PubMed ID: 28071010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intestinal microbiota; relevance to obesity and modulation by prebiotics and probiotics.
    da Silva ST; dos Santos CA; Bressan J
    Nutr Hosp; 2013; 28(4):1039-48. PubMed ID: 23889619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity.
    Remely M; Aumueller E; Merold C; Dworzak S; Hippe B; Zanner J; Pointner A; Brath H; Haslberger AG
    Gene; 2014 Mar; 537(1):85-92. PubMed ID: 24325907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guests in the gut.
    Diabetes Forecast; 2012 Nov; 65(11):78-9. PubMed ID: 23175947
    [No Abstract]   [Full Text] [Related]  

  • 25. The intricate association between gut microbiota and development of type 1, type 2 and type 3 diabetes.
    Bekkering P; Jafri I; van Overveld FJ; Rijkers GT
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1031-41. PubMed ID: 24138599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut microbiota dysbiosis associated with glucose metabolism disorders and the metabolic syndrome in older adults.
    Lippert K; Kedenko L; Antonielli L; Kedenko I; Gemeier C; Leitner M; Kautzky-Willer A; Paulweber B; Hackl E
    Benef Microbes; 2017 Aug; 8(4):545-556. PubMed ID: 28701081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gut dysbiosis and detection of "live gut bacteria" in blood of Japanese patients with type 2 diabetes.
    Sato J; Kanazawa A; Ikeda F; Yoshihara T; Goto H; Abe H; Komiya K; Kawaguchi M; Shimizu T; Ogihara T; Tamura Y; Sakurai Y; Yamamoto R; Mita T; Fujitani Y; Fukuda H; Nomoto K; Takahashi T; Asahara T; Hirose T; Nagata S; Yamashiro Y; Watada H
    Diabetes Care; 2014 Aug; 37(8):2343-50. PubMed ID: 24824547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging role of intestinal microbiota and microbial metabolites in metabolic control.
    Herrema H; IJzerman RG; Nieuwdorp M
    Diabetologia; 2017 Apr; 60(4):613-617. PubMed ID: 28013341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating Obesity and Metabolic Syndrome with Fecal Microbiota Transplantation.
    Marotz CA; Zarrinpar A
    Yale J Biol Med; 2016 Sep; 89(3):383-388. PubMed ID: 27698622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut reactions.
    Wallis C
    Sci Am; 2014 Jun; 310(6):30, 33. PubMed ID: 25004571
    [No Abstract]   [Full Text] [Related]  

  • 31. Could the beneficial effects of dietary calcium on obesity and diabetes control be mediated by changes in intestinal microbiota and integrity?
    Gomes JM; Costa JA; Alfenas RC
    Br J Nutr; 2015 Dec; 114(11):1756-65. PubMed ID: 26400630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microbiota, antibiotics, and obesity.
    Jess T
    N Engl J Med; 2014 Dec; 371(26):2526-8. PubMed ID: 25539109
    [No Abstract]   [Full Text] [Related]  

  • 33. [Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].
    Halmos T; Suba I
    Orv Hetil; 2016 Jan; 157(1):13-22. PubMed ID: 26708682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding.
    Cani PD; Delzenne NM; Amar J; Burcelin R
    Pathol Biol (Paris); 2008 Jul; 56(5):305-9. PubMed ID: 18178333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probiotic carbohydrates reduce intestinal permeability and inflammation in metabolic diseases.
    Strowski MZ; Wiedenmann B
    Gut; 2009 Aug; 58(8):1044-5. PubMed ID: 19592687
    [No Abstract]   [Full Text] [Related]  

  • 36. Gut microbiota and obesity: implications for fecal microbiota transplantation therapy.
    Kang Y; Cai Y
    Hormones (Athens); 2017 Jul; 16(3):223-234. PubMed ID: 29278509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intestinal microbiota and novel therapeutic perspectives for the treatment of metabolic diseases].
    Burcelin R; Chabo C; Blasco-Baque V; Sérino M; Amar J
    Med Sci (Paris); 2013; 29(8-9):800-6. PubMed ID: 24005637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Colon microbiota and constituents of metabolic syndrome].
    Lazebnik LB; Konev IuV
    Eksp Klin Gastroenterol; 2014; (5):33-9. PubMed ID: 25518498
    [No Abstract]   [Full Text] [Related]  

  • 39. Microbiota and epigenetic regulation of inflammatory mediators in type 2 diabetes and obesity.
    Remely M; Aumueller E; Jahn D; Hippe B; Brath H; Haslberger AG
    Benef Microbes; 2014 Mar; 5(1):33-43. PubMed ID: 24533976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities.
    Brunkwall L; Orho-Melander M
    Diabetologia; 2017 Jun; 60(6):943-951. PubMed ID: 28434033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.